A double-blind comparison of fentiazac and phenylbutazone in the treatment of acute tendinitis and bursitis

Summary

Seventy-four patients suffering from acute tendinitis/bursitis completed a double-blind trial to compare the effectiveness and tolerability of treatment with fentiazac with that of phenylbutazone. Patients received either 200 mg fentiazac or 400 mg phenylbutazone daily in divided doses, for 7 days. Swelling, redness, tenderness on pressure and range of motion were evaluated by the physician before, on Day 7 of therapy, and 7 days after completion of therapy. Patients kept daily records during therapy of the same parameters as well as of the degree of activity interference and overall pain. The results of the investigators' and patients' assessments showed equivalent improvement in all the parameters tested with both drugs. The improvement was maintained for at least 7 days in both groups and 75% of patients required no further treatment. Nearly 50% of patients complained of one or more side-effects, mostly mild in nature and, with the exception of heartburn in patients receiving fentiazac, there was no statistically significant difference in the incidence between the two groups. Laboratory investigations revealed no clinically significant differences in any of the parameters studied.

Key Words::

• Fentiazac
• phenylbutazone
• analgesics
• anti-inflammatory
• tendonitis
• bursitis